课题基金 / 基金详情

项目摘要

项目成果

Jian-Ting Zhang的其他基金

相关文献

中文摘要
翻译
描述(由申请人提供):多药耐药(MDR)是人类癌症成功化疗的主要问题。癌症细胞中耐多药的已知机制之一是介导抗癌药物外排的膜蛋白表达升高。已经确定了具有这种药物外排功能的三种主要膜蛋白:p -糖蛋白(Pgp)、多药耐药相关蛋白1 (MRP1)和乳腺癌耐药蛋白/米托蒽醌耐药蛋白(BCRP/MXR)。这些蛋白属于ATP结合盒(ABC)膜转运蛋白超家族,分别被命名为ABCB1、ABCC1和ABCG2。我们实验室的长期目标是了解肿瘤细胞中ABC转运蛋白介导的耐多药的分子机制并克服它。与人类ABCB1和ABCC1不同,人类ABCG2是一个半ABC转运体,其核苷酸结合结构域位于氨基末端,被认为是同源二聚体。然而,我们最近的研究表明它以同十二聚体的形式存在。在本应用中,我们计划验证人类ABCG2作为同型十二聚体而不是普遍的同型二聚体的假设,并且我们可以靶向寡聚化过程来逆转ABCG2介导的耐药。为此,我们计划完成以下五个具体目标:(1)确定人类ABCG2是同二聚体还是同十二聚体;(2)确定十二聚体形式的人ABCG2是否为功能性转运体;(3)确定人ABCG2的寡聚化是否发生在内质网(ER);(4)确定人ABCG2的羧基跨膜结构域是否参与了寡聚化;(5)通过破坏abcg2的寡聚过程来确定是否有可能逆转abcg2介导的耐药。印第安纳大学癌症研究所优秀的科学环境和慷慨的机构支持将极大地促进该项目成功的可能性。本研究获得的信息和探针将有助于我们了解abcg2介导的人药物转运的分子机制。这项工作也可能引导我们发现一类新的治疗药物,可以帮助克服耐药癌症。
英文摘要
DESCRIPTION (provided by applicant): Multidrug resistance (MDR) is a major problem for successful chemotherapy of human cancers. One of the known mechanisms of MDR in cancer cells is the elevated expression of membrane proteins that mediate the efflux of anticancer drugs. Three major membrane proteins that have this drug-efflux function have been identified: P-glycoprotein (Pgp), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein/mitoxantrone resistance protein (BCRP/MXR). These proteins belong to the ATP- binding cassette (ABC) membrane transporter superfamily and are also named as ABCB1, ABCC1, and ABCG2, respectively. The long-term goal of our laboratory is to understand the molecular mechanisms of and to overcome ABC transporter-mediated MDR in cancer cells. Unlike human ABCB1 and ABCC1, human ABCG2 is a half ABC transporter with its nucleotide binding domain located at the amino terminus and has been thought to function as a homodimer. However, our recent studies suggest that it exists as a homododecamer. In this application, we plan to test the hypothesis that human ABCG2 functions as a homododecamer rather than the prevailing homodimer and we can target the oligomerization process to reverse ABCG2-mediated drug resistance. To this end, we plan to accomplish the following five specific aims: (1) to determine if human ABCG2 is a homodimer or homododecamer; (2) to determine if the dodecameric form of human ABCG2 is a functional transporter; (3) to determine if the oligomerization of human ABCG2 occurs in the endoplasmic reticulum (ER); (4) to determine if the carboxyl transmembrane domain of human ABCG2 is responsible for oligomerization; (5) to determine if it is possible to reverse ABCG2-mediated drug resistance by disrupting its oligomerization process. The excellent scientific environment at Indiana University Cancer Research Institute and the generous institutional support will contribute enormously to the likelihood of success of this project. The information and probes obtained from this study will help us understand the molecular mechanism of human ABCG2-mediated drug transport. This work may also lead us to the discovery of a new class of therapeutic agents that can help overcome drug-resistant cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting FASN to eliminate metastatic breast cancer in the brain
Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway
Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway
Molecular targeting the translational control axis in Wnt/β-catenin signaling pathway